JP2007513073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513073A5 JP2007513073A5 JP2006538541A JP2006538541A JP2007513073A5 JP 2007513073 A5 JP2007513073 A5 JP 2007513073A5 JP 2006538541 A JP2006538541 A JP 2006538541A JP 2006538541 A JP2006538541 A JP 2006538541A JP 2007513073 A5 JP2007513073 A5 JP 2007513073A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- lymphoma
- composition
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 73
- 230000027455 binding Effects 0.000 claims 70
- 239000012634 fragment Substances 0.000 claims 63
- 239000000427 antigen Substances 0.000 claims 62
- 102000036639 antigens Human genes 0.000 claims 62
- 108091007433 antigens Proteins 0.000 claims 62
- 206010025323 Lymphomas Diseases 0.000 claims 41
- 208000003950 B-cell lymphoma Diseases 0.000 claims 30
- 239000005557 antagonist Substances 0.000 claims 27
- 229950004563 lucatumumab Drugs 0.000 claims 20
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims 19
- 210000004408 hybridoma Anatomy 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 10
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 10
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 10
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 10
- 230000003325 follicular Effects 0.000 claims 10
- 201000003444 follicular lymphoma Diseases 0.000 claims 10
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 9
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 5
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 5
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 5
- 208000017604 Hodgkin disease Diseases 0.000 claims 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 5
- 206010053574 Immunoblastic lymphoma Diseases 0.000 claims 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 5
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 5
- 201000003791 MALT lymphoma Diseases 0.000 claims 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 5
- 208000007452 Plasmacytoma Diseases 0.000 claims 5
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 5
- 238000012875 competitive assay Methods 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 201000009277 hairy cell leukemia Diseases 0.000 claims 5
- 201000006417 multiple sclerosis Diseases 0.000 claims 5
- 208000025113 myeloid leukemia Diseases 0.000 claims 5
- 230000001613 neoplastic effect Effects 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 210000004180 plasmocyte Anatomy 0.000 claims 5
- 230000004614 tumor growth Effects 0.000 claims 4
- 108010063916 CD40 Antigens Proteins 0.000 claims 3
- 238000009175 antibody therapy Methods 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 238000011260 co-administration Methods 0.000 claims 3
- 230000002195 synergetic effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51733703P | 2003-11-04 | 2003-11-04 | |
| US60/517,337 | 2003-11-04 | ||
| US52557903P | 2003-11-26 | 2003-11-26 | |
| US60/525,579 | 2003-11-26 | ||
| US56571004P | 2004-04-27 | 2004-04-27 | |
| US60/565,710 | 2004-04-27 | ||
| US61388504P | 2004-09-28 | 2004-09-28 | |
| US60/613,885 | 2004-09-28 | ||
| PCT/US2004/037159 WO2005044307A2 (en) | 2003-11-04 | 2004-11-04 | Methods of therapy for b cell-related cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011043231A Division JP2011105772A (ja) | 2003-11-04 | 2011-02-28 | Ｂ細胞に関連する癌に対する治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007513073A JP2007513073A (ja) | 2007-05-24 |
| JP2007513073A5 true JP2007513073A5 (enExample) | 2007-10-04 |
| JP4810431B2 JP4810431B2 (ja) | 2011-11-09 |
Family
ID=34577851
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538541A Expired - Fee Related JP4810431B2 (ja) | 2003-11-04 | 2004-11-04 | Ｂ細胞に関連する癌に対する治療方法 |
| JP2011043231A Withdrawn JP2011105772A (ja) | 2003-11-04 | 2011-02-28 | Ｂ細胞に関連する癌に対する治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011043231A Withdrawn JP2011105772A (ja) | 2003-11-04 | 2011-02-28 | Ｂ細胞に関連する癌に対する治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070098718A1 (enExample) |
| EP (3) | EP1684869B1 (enExample) |
| JP (2) | JP4810431B2 (enExample) |
| AT (1) | ATE516819T1 (enExample) |
| CA (1) | CA2544368C (enExample) |
| CY (1) | CY1112473T1 (enExample) |
| DK (1) | DK1684869T3 (enExample) |
| PL (1) | PL1684869T3 (enExample) |
| PT (1) | PT1684869E (enExample) |
| WO (1) | WO2005044307A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US20070110754A1 (en) * | 2003-11-04 | 2007-05-17 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| US20070098717A1 (en) * | 2003-11-04 | 2007-05-03 | Chiron Corporation | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
| KR101403910B1 (ko) * | 2003-11-04 | 2014-06-09 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 길항제 항-ｃｄ４０ 단클론성 항체 및 그것의 사용 방법 |
| PL1684805T3 (pl) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40 |
| WO2005108428A2 (en) * | 2004-02-26 | 2005-11-17 | Compugen Ltd. | Cd40 splice variants and their uses |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| CN101870730A (zh) | 2005-03-31 | 2010-10-27 | 生物医药股份有限公司 | 抗cd20单克隆抗体 |
| EP1894012A2 (en) * | 2005-05-18 | 2008-03-05 | Novartis AG | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| ES2400660T3 (es) * | 2005-11-01 | 2013-04-11 | Novartis Ag | Usos de anticuerpos anti-CD40 |
| WO2007053661A2 (en) * | 2005-11-01 | 2007-05-10 | Novartis Ag | Uses of anti-cd40 antibodies |
| CN101426817B (zh) | 2006-04-21 | 2013-07-10 | 诺华有限公司 | 拮抗性抗-cd40抗体药物组合物 |
| US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| US20110002934A1 (en) * | 2007-11-09 | 2011-01-06 | Novartis Ag | Uses of anti-cd40 antibodies |
| JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| EA201170940A1 (ru) * | 2009-01-16 | 2012-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| ES2653639T3 (es) | 2011-02-28 | 2018-02-08 | Napajen Pharma, Inc. | Complejo ácido nucleico-polisacárido |
| PL2683406T3 (pl) | 2011-03-11 | 2019-11-29 | Beth Israel Deaconess Medical Ct Inc | Przeciwciała anty-cd40 i ich zastosowania |
| KR102096224B1 (ko) | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| EP2992013B1 (en) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| UA125637C2 (uk) | 2014-10-29 | 2022-05-11 | Тева Фармасьютікалз Острейліа Пті Лтд | ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b |
| BR112018004296B1 (pt) | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| CN109071665B (zh) | 2016-04-18 | 2022-11-01 | 塞德斯医疗公司 | 结合人cd40的激动性抗体及其用途 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| BR112019000512A2 (pt) | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
| CN112638375A (zh) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | 通过后细胞信号传导因子的调节来增加免疫活性 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| KR20230165276A (ko) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도 |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| AU680102B2 (en) | 1993-12-23 | 1997-07-17 | Immunex Corporation | Method of preventing or treating disease characterized by neoplastic cells expressing CD40 |
| WO1995023512A1 (en) | 1994-03-03 | 1995-09-08 | Alexion Pharmaceuticals, Inc. | Terminal complement inhibitor fusion genes and proteins |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
| JP3919235B2 (ja) | 1997-06-13 | 2007-05-23 | ジェネンテク，インコーポレイテッド | 抗体製剤 |
| KR101063278B1 (ko) | 1998-08-11 | 2011-09-07 | 바이오겐 아이덱 인크. | Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제 |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| JP2003508016A (ja) | 1999-04-16 | 2003-03-04 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| AU2001259215A1 (en) * | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| AU6461201A (en) * | 2000-07-12 | 2002-01-21 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| JP2004508420A (ja) * | 2000-09-18 | 2004-03-18 | アイデック ファーマスーティカルズ コーポレイション | Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法 |
| DE60143535D1 (de) | 2000-10-02 | 2011-01-05 | Novartis Vaccines & Diagnostic | Humane antikörper gegen cd40 |
| KR100750998B1 (ko) * | 2000-10-05 | 2007-08-22 | 니폰 가야꾸 가부시끼가이샤 | 폴리페놀수지, 그의 제조방법, 에폭시수지 조성물 및 그의용도 |
| WO2003029296A1 (en) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CN1281599C (zh) * | 2003-05-15 | 2006-10-25 | 中国科学院上海有机化学研究所 | 香豆素类化合物和合成方法 |
| US20070098717A1 (en) * | 2003-11-04 | 2007-05-03 | Chiron Corporation | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
| US20070110754A1 (en) * | 2003-11-04 | 2007-05-17 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| PL1684805T3 (pl) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40 |
| KR101403910B1 (ko) * | 2003-11-04 | 2014-06-09 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 길항제 항-ｃｄ４０ 단클론성 항체 및 그것의 사용 방법 |
| EP1637075A1 (fr) * | 2004-09-20 | 2006-03-22 | Centre Hospitalier Regional Universitaire de Lille | Procédé et dispositif d'évaluation de la douleur chez un être vivant |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| JP6039343B2 (ja) | 2012-10-04 | 2016-12-07 | キヤノン株式会社 | 電子機器、電子機器の制御方法、プログラム、記憶媒体 |
-
2004
- 2004-11-04 AT AT04810517T patent/ATE516819T1/de active
- 2004-11-04 CA CA2544368A patent/CA2544368C/en not_active Expired - Fee Related
- 2004-11-04 EP EP04810517A patent/EP1684869B1/en not_active Expired - Lifetime
- 2004-11-04 DK DK04810517.5T patent/DK1684869T3/da active
- 2004-11-04 EP EP07075155A patent/EP1844815B1/en not_active Expired - Lifetime
- 2004-11-04 PL PL04810517T patent/PL1684869T3/pl unknown
- 2004-11-04 US US10/578,401 patent/US20070098718A1/en not_active Abandoned
- 2004-11-04 WO PCT/US2004/037159 patent/WO2005044307A2/en not_active Ceased
- 2004-11-04 JP JP2006538541A patent/JP4810431B2/ja not_active Expired - Fee Related
- 2004-11-04 PT PT04810517T patent/PT1684869E/pt unknown
- 2004-11-04 EP EP10075256A patent/EP2236172A1/en not_active Withdrawn
-
2011
- 2011-02-28 JP JP2011043231A patent/JP2011105772A/ja not_active Withdrawn
- 2011-10-14 CY CY20111100978T patent/CY1112473T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007513073A5 (enExample) | ||
| JP2007512243A5 (enExample) | ||
| AU2022202796B2 (en) | Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof | |
| JP6215429B2 (ja) | Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| TWI436770B (zh) | 包含專一性辨識ｃｄ３８之抗體及阿糖胞苷（ｃｙｔａｒａｂｉｎｅ）之抗腫瘤組合 | |
| JP2004510752A5 (enExample) | ||
| JP2007526908A5 (enExample) | ||
| JP2020504723A5 (enExample) | ||
| US12194095B2 (en) | Combinations and uses thereof | |
| JP2020527332A5 (enExample) | ||
| RU2010123363A (ru) | Применения анти-cd40-антител | |
| JP2011521647A (ja) | 抗ｆｌｔ３抗体 | |
| HK1251152A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| RU2756405C2 (ru) | Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения | |
| TW201803600A (zh) | 以ｐｂｄ為主之抗體藥物結合物及ｆｌｔ３抑制劑之組合 | |
| JP2020522543A5 (enExample) | ||
| CN111094353A (zh) | 用于癌症的组合治疗 | |
| JP2021501800A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| WO2012076688A1 (en) | Combination comprising a derivative of the family of the combretastatins and cetuximab | |
| JPWO2021050857A5 (enExample) | ||
| HK40023127A (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| CN119546640A (zh) | 用于治疗癌症的包含SIRPα融合蛋白和抗CD19抗体的组合疗法 | |
| JPWO2023034564A5 (enExample) | ||
| JPWO2022053652A5 (enExample) |